This move is archived. Current quotes and coverage live on the stock page.
Follow MBX
Microbix Biosystems Inc. is showing positive momentum as it rises in today's trading session.
Microbix Biosystems Inc. (MBX.TO) is gaining today, with shares up by 1.79% to a real-time price of CA$0.28. This increase reflects a growing confidence in the company, despite its previous challenges.
Advertisement
Microbix Biosystems Inc.
MBX.TO
MBX.TO
Microbix Biosystems Inc.
WealthAwesomeMarket cap
$43.15M
52W high
$0.33
52W low
$0.21
1W change
+0.00%
Beta
0.54
Analyst Price Targets
Based on analyst covering MBX · as of Sep 17, 2026
Wall Street analysts forecast MBX stock price to rise 29.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.40
+29.0% Upside
Current Price
C$0.31
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MBX's historical volatility
30-Day Vol
52.0%
Annualized
90-Day Vol
47.8%
Annualized
Trend (90d)
-0.0%
Annualized drift
90d Mean
C$0.31
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.31 | C$0.26 – C$0.37 |
| 60 trading days | C$0.31 | C$0.24 – C$0.40 |
| 90 trading days | C$0.31 | C$0.23 – C$0.42 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors might see this uptick as a sign of recovery and potential for future growth in Microbix's operations.
Microbix Biosystems Inc. Market Cap Reaches CA$40.4 Million
With a market cap of CA$40.4 million, Microbix is still a small player in the biotech field, which can lead to volatility in its stock price.
Bull case
Microbix recently reported a 17% revenue growth in Q3 fiscal 2026, suggesting the company is on a recovery path. This positive trend could attract investors looking for growth opportunities in the biotech sector.
Bear case
Despite today’s gains, Microbix still faces challenges. The company has a history of net losses and does not offer dividends, which may make it less appealing to risk-averse investors.
Advertisement
Recent Performance Overview
Microbix's stock is rising today, reflecting a positive sentiment in the market. The company reported a 1.79% increase, bringing its share price to CA$0.28. This uptick may be attributed to the recent announcement of a 17% revenue growth in Q3 fiscal 2026, which has likely bolstered investor confidence.
Market Position and Future Outlook
With a market cap of CA$40.4 million, Microbix remains a small player in the biotech industry. Investors should consider the company's ongoing efforts to rebuild its revenue streams and address past challenges. While the current gains are promising, the lack of dividends and a history of net losses could pose risks for potential investors. For more insights, check out the Microbix stock page.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
